First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: Should we stop separating cisplatin-eligible and -ineligible patients?

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages

  Sonpavde, Guru ^a   Galsky, Matthew D ^b   Vogelzang, Nicholas J ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Department of Hematology Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG CONTRAINDICATION; DRUG TREATMENT FAILURE; HUMAN; KIDNEY DYSFUNCTION; LETTER; OVERALL SURVIVAL; PATIENT CARE PLANNING; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; UROTHELIUM; UROTHELIUM CARCINOMA; AGE; COMORBIDITY; KIDNEY DISEASE; NOTE; URINARY TRACT CANCER;

AGE FACTORS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; KIDNEY DISEASES; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 77957597563     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.1047     Document Type: Letter

References (18)

1. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569, 1997 (Pubitemid 27289886)
2. Sternberg CN, de Mulder P, Schornagel JH, et al: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50-54, 2006 (Pubitemid 41814532)
3. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608, 2005 (Pubitemid 46224062)
4. Bellmunt J, von der Maase H, Mead GM, et al: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy: EORTC30987/Intergroup Study. J Clin Oncol 25:242s, 2007 (suppl; abstr LBA5030)
5. Dash A, Galsky MD, Vickers AJ, et al: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506-513, 2006 (Pubitemid 44107210)
6. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999 (Pubitemid 29470648)
7. Bellmunt J, Ribas A, Eres N, et al: Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966-1972, 1997
8. Dogliotti L, Carteni G, Siena S, et al: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial. Eur Urol 52:134-141, 2007 (Pubitemid 46803003)
9. Petrioli R, Frediani B, Manganelli A, et al: Comparison between a cisplatin-containing regimen and a carboplatin- containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study. Cancer 77:344-351, 1996
10. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: Phase II results of EORTC study 30986. J Clin Oncol 27:5634-5639, 2009
11. National Institutes of Health: ClinicalTrials.gov. http://www. ClinicalTrials.Gov
12. Hussain MH, MacVicar GR, Petrylak DP, et al: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218-2224, 2007 (Pubitemid 46954646)
13. Hainsworth JD, Meluch AA, Litchy S, et al: Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103:2298-2303, 2005 (Pubitemid 40686574)
14. Hussain M, Vaishampayan U, Du W, et al: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19:2527-2533, 2001 (Pubitemid 32391224)
15. deVere White RW, Lara PN Jr, Goldman B, et al: A sequential treatment approach to myoinvasive urothelial cancer: A phase II Southwest Oncology Group trial (S0219). J Urol 181:2476-2480, 2009; discussion 2480-2481
16. Smith DC, Mackler NJ, Dunn RL, et al: Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol 180:2384-2388, 2008; discussion 2388
17. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 99:847-857, 2007
18. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003 (Pubitemid 46606423)